0001209191-22-024859.txt : 20220419 0001209191-22-024859.hdr.sgml : 20220419 20220419195948 ACCESSION NUMBER: 0001209191-22-024859 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220418 FILED AS OF DATE: 20220419 DATE AS OF CHANGE: 20220419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Detheux Michel CENTRAL INDEX KEY: 0001816196 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 22836072 MAIL ADDRESS: STREET 1: C/O ITEOS THERAPEUTICS, INC. STREET 2: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-18 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001816196 Detheux Michel 321 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Chief Executive Officer Common Stock 2022-04-18 4 M 0 11500 4.23 A 37763 D Common Stock 2022-04-18 4 S 0 11467 31.87 D 26296 D Common Stock 2022-04-18 4 S 0 33 32.64 D 26263 D Stock Option (Right to Buy) 4.23 2022-04-18 4 M 0 11500 0.00 D 2030-05-01 Common Stock 11500 144464 D Stock Option (Right to Buy) 4.23 2030-05-01 Common Stock 185000 185000 I By MG3A The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. /s/ Adi Osovsky, as Attorney-in-Fact 2022-04-19